
|Videos|November 16, 2016
- NSCLC (Issue 11)
- Volume 4
- Issue 2
The Significance of Surgery Quality in NSCLC
Author(s)Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD, medical oncologist, Baptist Memorial Medical Group, discusses the significance of surgery quality in non-small cell lung cancer (NSCLC).
Advertisement
Articles in this issue
about 9 years ago
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLCabout 9 years ago
Clinical Trials Exploring Bevacizumab in NSCLCabout 9 years ago
Expert Explores Treatments for Biomarker-Negative Lung Cancerabout 9 years ago
Erlotinib/Bevacizumab Combo Warrants Consideration for EGFR+ NSCLCabout 9 years ago
Practice-Changing Translational Advances Predicted for NSCLCabout 9 years ago
Addressing the Challenges of Treating Non-Driver NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5






































